Kidney Res Clin Pract.  2014 Mar;33(1):3-8.

Treatment of phosphate retention: The earlier the better?

Affiliations
  • 1Klinikum Coburg GmbH, Department of Nephrology, Coburg, Germany. patrick.biggar@t-online.de
  • 2Princess Margaret Hospital, Kowloon West Cluster Hospital Authority, Kowloon, Hong Kong SAR, China.

Abstract

Over the last 15 years, our knowledge and understanding of the underlying mechanisms involved in the regulation of calcium and phosphate homeostasis in chronic kidney disease have advanced dramatically. Contrary to general opinion in the 20th century that moderate hypercalcemia and hyperphosphatemia were acceptable in treating secondary hyperparathyroidism, the calcium and phosphate load is increasingly perceived to be a major trigger of vascular and soft tissue calcification. The current treatment options are discussed in view of historical developments and the expectations of the foreseeable future, focusing on the early treatment of hyperphosphatemia. At present, we lack in disputable evidence that active intervention using currently available drugs is of benefit to patients in chronic kidney disease stages 3 and 4.

Keyword

Calcification; Chronic kidney disease; FGF-23; Hyperphosphatemia; Phosphate binders; Prognosis

MeSH Terms

Calcium
Homeostasis
Humans
Hypercalcemia
Hyperparathyroidism, Secondary
Hyperphosphatemia
Prognosis
Renal Insufficiency, Chronic
Calcium
Full Text Links
  • KRCP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr